Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Dariusz R Wozniak & Timothy G Quinnell. (2015) Unmet needs of patients with narcolepsy: perspectives on emerging treatment options. Nature and Science of Sleep 7, pages 51-61.
Read now
Read now
Articles from other publishers (23)
Neetu Nair, John Patrick HegartyIIII, Carmen Mihaela Cirstea, Meng Gu, Carrina Brooke Appling & David Quentin Beversdorf. (2022) Relationship Between MR Spectroscopy-Detected Glutamatergic Neurometabolites and Changes in Social Behaviors in a Pilot Open-Label Trial of Memantine for Adults With Autism Spectrum Disorder. Frontiers in Psychiatry 13.
Crossref
Crossref
Shucai Jiang, Maotao He, Lifei Xiao, Yu Sun, Jiangwei Ding, Wenchao Li, Baorui Guo, Lei Wang, Yangyang Wang, Caibin Gao, Tao Sun & Feng Wang. (2022) Prenatal GABAB Receptor Agonist Administration Corrects the Inheritance of Autism-Like Core Behaviors in Offspring of Mice Prenatally Exposed to Valproic Acid. Frontiers in Psychiatry 13.
Crossref
Crossref
Shucai Jiang, Lifei Xiao, Yu Sun, Maotao He, Caibin Gao, Changliang Zhu, Haigang Chang, Jiangwei Ding, Wenchao Li, Yangyang Wang, Tao Sun & Feng Wang. (2022) The GABAB receptor agonist STX209 reverses the autism‑like behaviour in an animal model of autism induced by prenatal exposure to valproic acid. Molecular Medicine Reports 25:5.
Crossref
Crossref
Erin Henneberry, Martine Lamy, Kelli C. Dominick & Craig A. Erickson. (2021) Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder. Journal of Autism and Developmental Disorders 51:12, pages 4370-4394.
Crossref
Crossref
A. Nieto, T. Bailey, K. Kaczanowska & P. McDonald. 2022. Behavioral Neurobiology of GABAB Receptor Function. Behavioral Neurobiology of GABAB Receptor Function
81
118
.
Richard E. Frye, Daniel A. Rossignol, Lawrence Scahill, Christopher J. McDougle, Harris Huberman & Edward V. Quadros. (2020) Treatment of Folate Metabolism Abnormalities in Autism Spectrum Disorder. Seminars in Pediatric Neurology 35, pages 100835.
Crossref
Crossref
Martine Lamy, Ernest V. Pedapati, Kelli L. Dominick, Logan K. Wink & Craig A. Erickson. (2020) Recent Advances in the Pharmacological Management of Behavioral Disturbances Associated with Autism Spectrum Disorder in Children and Adolescents. Pediatric Drugs 22:5, pages 473-483.
Crossref
Crossref
Michael Telias. (2020) Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction. Current Pharmaceutical Design 25:41, pages 4394-4404.
Crossref
Crossref
Marie-Céline Frantz, Lucie P. Pellissier, Elsa Pflimlin, Stéphanie Loison, Jorge Gandía, Claire Marsol, Thierry Durroux, Bernard Mouillac, Jérôme A. J. Becker, Julie Le Merrer, Christel Valencia, Pascal Villa, Dominique Bonnet & Marcel Hibert. (2018) LIT-001, the First Nonpeptide Oxytocin Receptor Agonist that Improves Social Interaction in a Mouse Model of Autism. Journal of Medicinal Chemistry 61:19, pages 8670-8692.
Crossref
Crossref
Kristel De Groot & Jan W. Van Strien. (2018) Spontaneous resting-state gamma oscillations are not predictive of autistic traits in the general population. European Journal of Neuroscience 48:8, pages 2928-2937.
Crossref
Crossref
Martine Lamy & Craig A. Erickson. (2018) Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders. Current Problems in Pediatric and Adolescent Health Care 48:10, pages 250-264.
Crossref
Crossref
Richard E. Frye. (2018) Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents. CNS Drugs 32:8, pages 713-734.
Crossref
Crossref
Hayley P. Drozd, Sotirios F. Karathanasis, Andrei I. Molosh, Jodi L. Lukkes, D. Wade Clapp & Anantha Shekhar. 2018. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders. Genetic Models and Molecular Pathways Underlying Autism Spectrum Disorders
113
158
.
Russell G. Port, Christopher Gajewski, Elizabeth Krizman, Holly C. Dow, Shinji Hirano, Edward S. Brodkin, Gregory C. Carlson, Michael B. Robinson, Timothy P.L. Roberts & Steven J. Siegel. (2017) Protocadherin 10 alters γ oscillations, amino acid levels, and their coupling; baclofen partially restores these oscillatory deficits. Neurobiology of Disease 108, pages 324-338.
Crossref
Crossref
Margaret C. Grabb & Jogarao V.S. Gobburu. (2017) Challenges in developing drugs for pediatric CNS disorders: A focus on psychopharmacology. Progress in Neurobiology 152, pages 38-57.
Crossref
Crossref
Laurence Lalanne, Luisa Weiner & Gilles Bertschy. 2017. Handbook of Treatments for Autism Spectrum Disorder. Handbook of Treatments for Autism Spectrum Disorder
377
395
.
Ron Oberleitner, Uwe Reischl, Kamilla G. Gazieva, N. Nazneen, Jasjit S. Suri & Christopher J. Smith. 2016. Autism Imaging and Devices. Autism Imaging and Devices
355
370
.
Richard E. Frye, Manuel F. Casanova, S. Hossein Fatemi, Timothy D. Folsom, Teri J. Reutiman, Gregory L. Brown, Stephen M. Edelson, John C. Slattery & James B. Adams. (2016) Neuropathological Mechanisms of Seizures in Autism Spectrum Disorder. Frontiers in Neuroscience 10.
Crossref
Crossref
Richard E. FryeDaniel A. Rossignol. (2016) Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes. Clinical Medicine Insights: Pediatrics 10, pages CMPed.S38337.
Crossref
Crossref
Roberto Canitano. (2015) Mood Stabilizers in Children and Adolescents With Autism Spectrum Disorders. Clinical Neuropharmacology 38:5, pages 177-182.
Crossref
Crossref
Marlena Duda & Dennis P Wall. (2015) Rising interdisciplinary collaborations refine our understanding of autisms and give hope to more personalized solutions. Personalized Medicine 12:4, pages 359-369.
Crossref
Crossref
Ana Sastre, Nuria E Campillo, Carmen Gil & Ana Martinez. (2015) Therapeutic approaches for the future treatment of Fragile X. Current Opinion in Behavioral Sciences 4, pages 6-21.
Crossref
Crossref
Tatiana M. Kazdoba, Prescott T. Leach, Mu Yang, Jill L. Silverman, Marjorie Solomon & Jacqueline N. Crawley. 2016. Translational Neuropsychopharmacology. Translational Neuropsychopharmacology
1
52
.